Cover Image
市場調查報告書

疫苗佐劑市場預測 ∼2021年:各產品類型 (粒子狀、乳膠、病原體、皂素)、投藥途徑、疾病區分、用途、對象類別

Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

出版商 MarketsandMarkets 商品編碼 360822
出版日期 內容資訊 英文 158 Pages
訂單完成後即時交付
價格
Back to Top
疫苗佐劑市場預測 ∼2021年:各產品類型 (粒子狀、乳膠、病原體、皂素)、投藥途徑、疾病區分、用途、對象類別 Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021
出版日期: 2016年06月15日 內容資訊: 英文 158 Pages
簡介

全球疫苗佐劑的市場在預測期間內,預計以10.5%的年複合成長率發展,從2016年的4億6700萬美元,2021年成長到7億6940萬美元的規模。

本報告提供全球疫苗佐劑的市場調查,市場及產品概要,主要開發中產品,法律制度,影響市場成長因素及市場機會分析,產品類型、投藥途徑、疾病區分、用途、對象、地區/主要國家等各分類趨勢與市場規模的變化與預測,競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 各用途市場
  • 地區概要
  • 地區分析:各對象類別
  • 地區分析:各疾病種類
  • 生命週期分析:各地區

第5章 市場概要

  • 簡介
  • 市場動態
    • 推進因素
    • 阻礙要素
    • 市場機會
    • 課題
  • 主要開發中產品
  • 法律制度
    • 北美
    • 歐洲
    • 亞洲
    • 其他地區

第6章 市場分析:各產品類型

  • 簡介
  • 粒子書佐劑
  • 佐劑乳膠
  • 病原體成分
  • 混合佐劑
  • 其他

第7章 市場分析:各投藥途徑

  • 簡介
  • 肌肉內途徑
  • 皮下途徑
  • 鼻腔內途徑
  • 口服
  • 經皮
  • 其他

第8章 市場分析:各疾病種類

  • 簡介
  • 感染疾病
  • 癌症
  • 其他

第9章 市場分析:各用途

  • 簡介
  • 研究
  • 商用

第10章 市場分析:各對象類別

  • 簡介
  • 人體疫苗佐劑
  • 動物用疫苗佐劑

第11章 地區分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他
  • 亞洲
    • 中國
    • 印度
    • 其他
  • 其他地區

第12章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢
    • 協定、合作
    • 收購
    • 擴張
    • 其他

第13章 企業簡介

  • 簡介
  • BRENNTAG BIOSECTOR A/S
  • SEPPIC
  • CSL LIMITED
  • AGENUS, INC.
  • NOVAVAX, INC.
  • INVIVOGEN
  • SPI PHARMA, INC.
  • AVANTI POLAR LIPIDS, INC.
  • MPV TECHNOLOGIES, INC.
  • OZ BIOSCIENCES
    • 概要
    • 財務趨勢
    • 產品與服務
    • 策略
    • 發展趨勢等

第14章 附錄

圖表

目錄
Product Code: BT 4378

The vaccine adjuvants market is expected to reach USD 769.4 million by 2021 from USD 467.0 million in 2016, at a CAGR of 10.5%. The global vaccine adjuvants market is segmented based on product type, route of administration, disease type, applications, and application categories.

On the basis of type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Growth in this segment can primarily be attributed to increasing investments in research.

On the basis of route of administration, the market is segmented into subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Increasing prevalence of diseases and the need for new vaccine adjuvants with better efficacy will drive the growth of this market.

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by the rapidly increasing aging population and rising government funding in the North American countries.

The major factors contributing to the growth of the vaccine adjuvants market include increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on improved vaccination. Furthermore, increasing R&D spending as well as acquisitions, collaborations, and agreements by companies is another major factor driving the growth of this market.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccine adjuvants market. The report analyzes the vaccine adjuvants market by type, route of administration, disease type, applications, and target group
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccine adjuvants market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccine adjuvants market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various vaccine adjuvants across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET SEGMENTATION
    • 1.3.2. MARKETS COVERED
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. KEY INDICATORS
    • 2.1.1. INTRODUCTION
    • 2.1.2. MACROINDICATORS
      • 2.1.2.1. Rapid growth of aging population
      • 2.1.2.2. Incidence and prevalence of cancer
      • 2.1.2.3. Burden of infectious diseases
      • 2.1.2.4. Healthcare expenditure patterns
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. KEY DATA FROM SECONDARY SOURCES
  • 2.5. KEY DATA FROM PRIMARY SOURCES
  • 2.6. KEY INDUSTRY INSIGHTS
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. VACCINE ADJUVANTS MARKET OVERVIEW
  • 4.2. VACCINE ADJUVANTS MARKET, BY APPLICATION
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE VACCINE ADJUVANTS MARKET
  • 4.4. GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
  • 4.5. GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
  • 4.6. LIFECYCLE ANALYSIS, BY REGION, 2015

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing use of adjuvants in vaccine
      • 5.2.1.2. High prevalence of infectious and zoonotic diseases
      • 5.2.1.3. Increase in livestock and instances of diseases
      • 5.2.1.4. Increasing focus on immunization programs from various government bodies
      • 5.2.1.5. Technological advancements in aluminum hydroxide-based adjuvants
      • 5.2.1.6. Increasing focus and support on the discovery and development of vaccine adjuvants
      • 5.2.1.7. Increasing geriatric population
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of adjuvant research
      • 5.2.2.2. Stringent regulatory environment and time-consuming approvals
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Combination adjuvants
      • 5.2.3.2. Pandemic diseases
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Identification of adjuvants
    • 5.2.5. TRENDS
      • 5.2.5.1. Collaborations
  • 5.3. KEY PIPELINE PRODUCTS
  • 5.4. REGULATORY LANDSCAPE
    • 5.4.1. NORTH AMERICA
    • 5.4.2. EUROPE
      • 5.4.2.1. Manufacturing specifications
      • 5.4.2.2. Routine testing
      • 5.4.2.3. Stability
    • 5.4.3. ASIA
    • 5.4.4. ROW

6. GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE

  • 6.1. INTRODUCTION
  • 6.2. PARTICULATE ADJUVANTS
  • 6.3. ADJUVANT EMULSIONS
  • 6.4. PATHOGEN COMPONENTS
  • 6.5. COMBINATION ADJUVANTS
  • 6.6. OTHERS

7. GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1. INTRODUCTION
  • 7.2. INTRAMUSCULAR ROUTE
  • 7.3. SUBCUTANEOUS ROUTE
  • 7.4. INTRANASAL ROUTE
  • 7.5. ORAL ROUTE
  • 7.6. INTRADERMAL ROUTE
  • 7.7. OTHERS

8. GLOBAL VACCINE ADJUVANT MARKET, BY DISEASE TYPE

  • 8.1. INTRODUCTION
  • 8.2. INFECTIOUS DISEASES
  • 8.3. CANCER
  • 8.4. OTHERS

9. GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. RESEARCH APPLICATION
  • 9.3. COMMERCIAL APPLICATION

10. GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY

  • 10.1. INTRODUCTION
  • 10.2. HUMAN VACCINE ADJUVANTS
  • 10.3. VETERINARY VACCINE ADJUVANTS

11. GLOBAL VACCINE ADJUVANTS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. U.K.
    • 11.3.3. FRANCE
    • 11.3.4. REST OF EUROPE
  • 11.4. ASIA
    • 11.4.1. CHINA
    • 11.4.2. INDIA
    • 11.4.3. REST OF ASIA
  • 11.5. REST OF THE WORLD

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. AGREEMENTS & COLLABORATIONS
    • 12.3.2. ACQUISITIONS
    • 12.3.3. EXPANSIONS
    • 12.3.4. OTHERS

13. COMPANY PROFILE (Overview, Financial*, Products & Services, Strategy, and Developments)

  • 13.1. INTRODUCTION
  • 13.2. BRENNTAG BIOSECTOR A/S (A SUBSIDIARY OF BRENNTAG AG)
  • 13.3. SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
  • 13.4. CSL LIMITED
  • 13.5. AGENUS, INC.
  • 13.6. NOVAVAX, INC.
  • 13.7. INVIVOGEN
  • 13.8. SPI PHARMA, INC. (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC.)
  • 13.9. AVANTI POLAR LIPIDS, INC.
  • 13.10. MPV TECHNOLOGIES, INC.
  • 13.11. OZ BIOSCIENCES

*Details might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASING USE OF ADJUVANTS IN VACCINE-PREVENTABLE DISEASES DRIVES THE MARKET GROWTH
  • TABLE 2: HIGH COST OF ADJUVANT RESEARCH RESTRAINTS THE MARKET GROWTH
  • TABLE 3: COMBINED ADJUVANTS AND PANDEMIC DISEASES OFFER GROWTH OPPORTUNITIES FOR MARKET PLAYERS
  • TABLE 4: IDENTIFICATION OF ADJUVANTS CHALLENGES THE GROWTH OF THIS MARKET
  • TABLE 5: COLLABORATIONS OFFER GROWTH TRENDS FOR MARKET PLAYERS
  • TABLE 6: FDA APPROVED VACCINE ADJUVANTS
  • TABLE 7: LICENSED VACCINES CONTAINING ADJUVANTS
  • TABLE 8: EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS
  • TABLE 9: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021
  • TABLE 10: LIST OF PARTICULATE ADJUVANTS APPROVED FOR HUMAN USE (2015)
  • TABLE 11: PARTICULATE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 12: NORTH AMERICA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 13: EUROPE PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 14: ASIA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 15: LIST OF ADJUVANT EMULSIONS APPROVED FOR HUMAN USE (2015)
  • TABLE 16: ADJUVANTS EMULSION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 17: NORTH AMERICA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 18: EUROPE ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 19: ASIA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 20: PATHOGEN COMPONENTS AND ITS DESCRIPTION
  • TABLE 21: PATHOGEN COMPONENTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 22: NORTH AMERICA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 23: EUROPE PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 24: ASIA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 25: LIST OF COMBINATION ADJUVANT APPROVED FOR HUMAN USE (2015)
  • TABLE 26: COMBINATION ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 27: NORTH AMERICA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 28: EUROPE COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 29: ASIA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 30: OTHER ADJUVANTS AND ITS DESCRIPTION
  • TABLE 31: OTHERS ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 32: NORTH AMERICA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 33: EUROPE OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 34: ASIA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021(USD MILLION)
  • TABLE 35: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021(USD MILLION)
  • TABLE 36: INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 37: SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 38: INTRANASAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 39: ORAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 40: INTRADERMAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 41: OTHERS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 42: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014-2021(USD MILLION)
  • TABLE 43: NEW CASES OF DISEASES (2014)
  • TABLE 44: INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 45: CANCER DISEASE VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 46: OTHERS VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 47: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014-2021(USD MILLION)
  • TABLE 48: VACCINE ADJUVANTS MARKET, BY RESEARCH APPLICATION, BY REGION, 2014-2021(USD MILLION)
  • TABLE 49: VACCINE ADJUVANTS MARKET, BY COMMERCIAL APPLICATION, BY REGION, 2014-2021(USD MILLION)
  • TABLE 50: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014-2021 (USD MILLION)
  • TABLE 51: LIST OF ADJUVANTS APPROVED FOR HUMAN USE BY FDA
  • TABLE 52: HUMAN VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 53: VETERINARY VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021(USD MILLION)
  • TABLE 54: VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 55: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 57: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 58: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 59: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 60: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014-2021(USD MILLION)
  • TABLE 61: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014-2021(USD MILLION)
  • TABLE 62: NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014-2021(USD MILLION)
  • TABLE 63: U.S.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021, (USD MILLION)
  • TABLE 64: CANADA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021(USD MILLION)
  • TABLE 65: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 66: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 67: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014-2021(USD MILLION)
  • TABLE 68: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014-2021(USD MILLION)
  • TABLE 69: EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014-2021 (USD MILLION)
  • TABLE 70: GERMANY: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: U.K.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: FRANCE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 73: REST OF EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 75: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 76: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014-2021(USD MILLION)
  • TABLE 77: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014-2021(USD MILLION)
  • TABLE 78: ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014-2021(USD MILLION)
  • TABLE 79: CHINA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 80: INDIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 81: REST OF ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 82: REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 83: REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 84: REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014-2021(USD MILLION)
  • TABLE 85: REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014-2021(USD MILLION)
  • TABLE 86: REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014-2021(USD MILLION)
  • TABLE 87: AGREEMENTS & COLLABORATIONS, 2015
  • TABLE 88: ACQUISITIONS, 2015-2016
  • TABLE 89: EXPANSIONS, 2014
  • TABLE 90: OTHERS, 2014-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: INCREASE IN AGING POPULATION, BY COUNTRY (2010 VS. 2015)
  • FIGURE 3: PERCENTAGE INCREASE IN AGING POPULATION, BY REGION (1980-2010 VS. 2010-2040)
  • FIGURE 4: GLOBAL BURDEN OF CANCER, BY REGION (2005-2030)
  • FIGURE 5: NUMBER OF NEW CANCER CASES BY COUNTRY
  • FIGURE 6: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES, 2000 VS. 2012
  • FIGURE 7: HEALTHCARE SPENDING MATRIX, BY COUNTRY (2013)
  • FIGURE 8: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 9: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 10: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 11: DATA TRIANGULATION METHODOLOGY
  • FIGURE 12: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 13: GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2016 VS. 2021 (USD MILLION)
  • FIGURE 14: GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 15: GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
  • FIGURE 16: GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2016 VS. 2021 (USD MILLION)
  • FIGURE 17: GLOBAL VACCINE ADJUVANTS MARKET, BY REGION, 2016 (USD MILLION)
  • FIGURE 18: THE VACCINE ADJUVANTS MARKET IS EXPECTED TO SHOWCASE HIGH GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
  • FIGURE 19: THE RESEARCH APPLICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 20: ASIAN COUNTRIES ARE EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 21: THE HUMAN VACCINE ADJUVANTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 22: THE INFECTIOUS DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2021
  • FIGURE 23: ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 24: THE PARTICULATE ADJUVANTS SEGMENT IS THE LARGEST SEGMENT OF THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
  • FIGURE 25: THE INTRANASAL ROUTE OF ADMINISTRATION SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD FROM 2016 TO 2021
  • FIGURE 26: THE CANCER DISEASE TYPE SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 27: CANCER INCIDENCE, BY REGION, 2012-2020
  • FIGURE 28: THE RESEARCH APPLICATION SEGMENT IS THE LARGEST IN THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
  • FIGURE 29: HUMAN VACCINE ADJUVANTS ACCOUNTS FOR THE LARGEST SHARE IN VACCINE ADJUVANT MARKET, BY APPLICATION CATEGORY, IN 2016
  • FIGURE 30: ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 31: NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
  • FIGURE 32: EUROPEAN VACCINE ADJUVANTS MARKET SNAPSHOT
  • FIGURE 33: ASIA: VACCINE ADJUVANTS MARKET SNAPSHOT
  • FIGURE 34: AGREEMENTS & COLLABORATIONS WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS, 2013-2016
  • FIGURE 35: GLOBAL VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015
  • FIGURE 36: BATTLE FOR MARKET SHARE: AGREEMENTS & COLLABORATIONS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
  • FIGURE 37: PRODUCT BENCHMARKING FOR MAJOR PLAYERS
  • FIGURE 38: COMPANY SNAPSHOT: BRENNTAG AG
  • FIGURE 39: COMPANY SNAPSHOT: AIR LIQUIDE GROUP
  • FIGURE 40: COMPANY SNAPSHOT: CSL LIMITED
  • FIGURE 41: COMPANY SNAPSHOT: AGENUS, INC.
  • FIGURE 42: COMPANY SNAPSHOT: NOVAVAX, INC.
Back to Top